NEURON-PD: Neural Control of Breathing in Parkinson's Disease

Sponsor
Radboud University Medical Center (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06074614
Collaborator
(none)
30
15

Study Details

Study Description

Brief Summary

Breathing is a complex process, which can be controlled through voluntary command or neural control. Parkinson's disease (PD) is a progressive neurological disorder. Many individuals with PD experience respiratory problems, such as coughing difficulties or shortness of breath. Changes in neural control of breathing could be part of the reason of these respiratory problems. This study will measure whether neural control of breathing is impaired in individuals with PD compared to healthy individuals.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Hypercapnic ventilatory response
  • Diagnostic Test: Respiratory related evoked potential
  • Diagnostic Test: Transcranial magnetic stimulation

Detailed Description

Rationale: Parkinson's disease (PD) is a progressive neurological disorder, characterised by loss of dopaminergic neurons. Respiratory dysfunction is common in patients with PD and can lead to pneumonia, which is a common cause of death in PD. However, the exact mechanism of respiratory dysfunction in PD is unknown. The complex process of neural control of breathing may be involved, but this is understudied. This is partly caused by methodological limitations to quantify neural control of breathing. In this study, we will use respiratory neurophysiological methods to determine whether neural control of breathing is impaired in Parkinson's disease. These techniques are hypercapnic ventilatory response, respiratory related evoked potentials and transcranial magnetic stimulation. This study will test the hypothesis that the neural control of breathing is impaired in individuals with PD compared to healthy subjects.

Objective: Primary Objective: To identify disease (Parkinson's disease) specific alterations in neural control of breathing by using respiratory neurophysiological techniques.

Study design: Exploratory cross-sectional study.

Study population: Healthy subjects (n=15) and patients with Parkinson's disease (n=15) >18 years old.

Main study parameters/endpoints:
  • Hypercapnic ventilatory response curve (HCVR): HCVR will be determined using the CO2-rebreathing technique.

  • Respiratory related evoked potential (RREP): RREP is a measure of cerebral cortical activity elicited by a short inspiratory occlusion.

  • Transcranial magnetic stimulation (TMS) diaphragm: TMS is an established tool for investigating the cortical excitability related to breathing.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The risk of this study for the participants is negligible. Subjects do not directly benefit from participating in this study. The scientific benefit of this study is to achieve a better understanding of the neural control of breathing in Parkinson's disease. The outcomes of this study may give rise to future new treatments in Parkinson's disease. The burden of the separate study procedures is relatively small: there are no invasive procedures and patients continue their medication as usual. However, the total time of the visit and the collective burden of the experiments may be perceived as strenuous. Therefore, subjects will be explicitly informed about this aspect of the study, and enough breaks will be scheduled in the program.

Study Design

Study Type:
Observational
Anticipated Enrollment :
30 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
Neural Control of Breathing in Parkinson's Disease: an Exploratory Study
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
May 1, 2024
Anticipated Study Completion Date :
Jan 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Parkison's disease

Participants with clinically confirmed Parkinson's disease, Hoehn and Yahr stage 1 to 3.

Diagnostic Test: Hypercapnic ventilatory response
Control of breathing is predominantly regulated by feedback of the central chemoreceptors. All chemoreceptors are sensitive to changes in partial pressure of carbon dioxide and via acid-base reactions to hydrogen concentration. The hypercapnic ventilatory response test shows the relationship between end-tidal PCO2 and the resulting minute ventilation.

Diagnostic Test: Respiratory related evoked potential
The RREP is a measure of cerebral cortical activity elicited by short inspiratory occlusion or breathing against inspiratory resistive loads and quantifies the initial arrival and further processing of sensory afferent respiratory information in the cortex.

Diagnostic Test: Transcranial magnetic stimulation
Transcranial magnetic stimulation of the diaphragm is an established tool for investigating the cortical excitability related to breathing. TMS will be delivered over the vertex using a magnetic stimulator and a 110mm double cone coil.

Healthy controls

Participants without Parkinson's disease.

Diagnostic Test: Hypercapnic ventilatory response
Control of breathing is predominantly regulated by feedback of the central chemoreceptors. All chemoreceptors are sensitive to changes in partial pressure of carbon dioxide and via acid-base reactions to hydrogen concentration. The hypercapnic ventilatory response test shows the relationship between end-tidal PCO2 and the resulting minute ventilation.

Diagnostic Test: Respiratory related evoked potential
The RREP is a measure of cerebral cortical activity elicited by short inspiratory occlusion or breathing against inspiratory resistive loads and quantifies the initial arrival and further processing of sensory afferent respiratory information in the cortex.

Diagnostic Test: Transcranial magnetic stimulation
Transcranial magnetic stimulation of the diaphragm is an established tool for investigating the cortical excitability related to breathing. TMS will be delivered over the vertex using a magnetic stimulator and a 110mm double cone coil.

Outcome Measures

Primary Outcome Measures

  1. Hypercapnic ventilatory response curve [baseline - during the test]

    Sensitivity slope of the ventilation increase per unit increase in PetCO2, as measured with a rebreathing technique.

  2. Respiratory related evoked potential [baseline - during the test]

    A measure of cerebral cortical activity elicited by a short inspiratory occlusion, expressed in the presence, latency and amplitude of components Nf, P1, N1, P2 and P3.

  3. Transcranial magnetic stimulation [baseline - during the test]

    Interstimulus interval curves, using a conditioning stimulus at 80% and a test stimulus at 125%.

Secondary Outcome Measures

  1. FVC [baseline - during the test]

    Forced vital capacity.

  2. FEV1 [baseline - during the test]

    Forced expiratory volume in 1 second.

  3. MIP [baseline - during the test]

    Maximal inspiratory pressure.

  4. MEP [baseline - during the test]

    Maximal expiratory pressure.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Healthy subjects: competent adult (>18 years) volunteers

  • Patients: adult (<18 years) patients with Parkinson's disease, clinically confirmed by a movement disorder specialised neurologist with Hoehn and Yahr staging 1 to 3

  • Willingness and ability to understand nature and content of the study

  • Ability to participate and comply with study requirements

Exclusion Criteria:
  • Healthy subjects: previous or ongoing diseases of the central nervous system

  • Patients: previous or ongoing diseases of the central nervous system, other than Parkinson's disease

  • History of or current psychiatric treatment

  • History of or current brain surgery or epilepsy, unclusing deep brain stimulation

  • Neuromuscular disorders

  • Pre-existing pulmonary disease, such as chronic obstructive pulmonary disease, asthma or pulmonary fibrosis

  • TMS incompatibility (metal parts in head or neck, skin allergies)

  • Implanted cardiac pacemaker or defibrillator, neurostimulator, cochlear implant or medical infusion device

  • Large or ferromagnetic metal parts in the head (exept for a dental wire)

  • Pregnancy

  • Smoking

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Radboud University Medical Center

Investigators

  • Principal Investigator: Jonne Doorduin, PhD, Radboud University Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Radboud University Medical Center
ClinicalTrials.gov Identifier:
NCT06074614
Other Study ID Numbers:
  • NL84745.091.23
First Posted:
Oct 10, 2023
Last Update Posted:
Oct 10, 2023
Last Verified:
Sep 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Radboud University Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 10, 2023